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Aims: The loss of cholinergic function in the central nervous system contributes signiﬁcantly to the cognitive
decline associated with advanced age and dementias. Huperzine A (HupA) is a selective inhibitor of
acetylcholinesterase (AChE) and has been shown to signiﬁcantly reduce cognitive impairment in animal
models of dementia. Based on the importance of astrocytes in physiological and pathological brain activities,
we investigated the effect of HupA and tacrine on S100B secretion in primary astrocyte cultures. S100B is
an astrocyte-derived protein that has been proposed to be a marker of brain injury.
Main methods: Primary astrocyte cultures were exposed to HupA, tacrine, cholinergic agonists, and S100B
secretion was measured by enzyme-linked immunosorbent assay (ELISA) at 1 and 24 h.
Key ﬁndings: HupA, but not tacrine, at 100 μM signiﬁcantly increased S100B secretion in astrocyte cultures.
Nicotine (at 100 and 1000 μM) was able to stimulate S100B secretion in astrocyte cultures.
Signiﬁcance: Our data reinforce the idea that AChE inhibitors, particularly HupA, do not act exclusively on the
acetylcholine balance. This effect of HupA could contribute to improve the cognitive deﬁcit observed in
patients, which are attributed to cholinergic dysfunction. In addition, for the ﬁrst time, to our knowledge,
these data indicate that S100B secretion can be modulated by nicotinic receptors, in addition to glutamate,
dopamine and serotonin receptors.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Huperzine A (HupA), a Lycopodium alkaloid isolated from the
Chinese herb Huperzia serrata, (Ma et al., 2007; Wang et al., 1986)
is a selective inhibitor of acetylcholinesterase (AChE) and has been
shown to signiﬁcantly reduce cognitive impairment in animal models
of dementia and in Alzheimer's disease (AD) patients in China (Wang
et al., 2006, 2009). Compared with other AChE inhibitors, e.g. tacrine,
HupA demonstrates a better passage through the blood–brain barrier,
higher oral bioavailability, longer duration of AChE inhibition, fewer
peripheral side effects, and is devoid of dose-limiting hepatotoxicity
(Bai et al., 2000; Liang and Tang, 2004; Tang, 1996; Tang et al.,
1994; Wang and Tang, 1998a; Xiong and Tang, 1995).
AD exhibits several neurochemical alterations including β-peptide
amyloidosis, inﬂammation and oxidative stress, leading to neuronal
population destruction, especially of cholinergic neurons (Davies
and Maloney, 1976; Geula et al., 2008; Mufson et al., 2002, 2008;
Verdier et al., 2004). This loss of cholinergic function in the central
nervous system contributes signiﬁcantly to the cognitive decline, ICBS, UFRGS, Ramiro Barcelos,
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OA license.associated with advanced age and AD (Bartus, 2000; Bartus et al.,
1982; Schliebs and Arendt, 2011; Terry and Buccafusco, 2003) and has
justiﬁed the use of AChE inhibitors as a strategy for patients with AD
(Birks, 2006; Giacobini, 2000; Nordberg and Svensson, 1998; Talesa,
2001; Whitehouse, 1993). Moreover, many other neuroprotective
effects of these compounds, in addition to AChE inhibition, have been
described (Nordberg, 2006; Racchi et al., 2004; Takatori, 2006). Some
studies have found that HupA displays neuroprotective properties
with multi-target effects (Zhang and Tang, 2006; Zhang et al., 2008a,
2008b). HupA has improved chronic inﬂammation and cognitive
decline in diverse animal models of dementia (Wang et al., 2001,
2010; Wang and Tang, 1998b; Zhang et al., 2004; Zhou et al., 2001).
S100B, a calcium-binding protein, produced and secreted by
astrocytes in the central nervous system, plays a regulatory role in
the cytoskeleton and cell cycle (Donato et al., 2009). Extracellular
S100B works as a neurotrophic cytokine and has been proposed as a
marker for brain injury, including that seen in AD (Goncalves et al.,
2008). In fact, it has been reported that this protein could affect
neuronal β-amyloid protein synthesis (Li et al., 1998). On the other
hand, we have observed decreased levels of this protein in the
cerebrospinal ﬂuid in rat models of dementia, including chronic
cerebral hypoperfusion (Vicente et al., 2009), intracerebroventricular
administration of streptozotocin (Rodrigues et al., 2009) and okadaic
acid (Costa et al., 2012).
Fig. 1. Effect of Huperzine A (HupA) on S100B secretion and content. Astrocyte cultures
were incubated with HupA (0.1, 1, 10 and 100 μM) and the S100B levels in the medium
were measured for 1 h (A) and 24 h (B), as well as the S100B content (C) by ELISA.
Each value is the mean (± standard error) of ﬁve independent experiments performed
in triplicate, expressed as a percentage of the control (indicated by dashed line).
***pb0.001 compared to control (one-way ANOVA followed by Dunnet's post-hoc
assay).
702 P. Lunardi et al. / Life Sciences 92 (2013) 701–707S100B secretion appears to be modulated by antipsychotic (Nardin
et al., 2011; Steiner et al., 2009) and anti-depressive drugs (Manev
and Manev, 2002; Tramontina et al., 2008), commonly used for
the symptomatic treatment of dementia. However, the effect of AChE
inhibitors and cholinergic agonists on S100B secretion has not been
investigated. Considering the importance of astrocytes in physiological
and pathological brain activities (Halassa et al., 2009; Halassa and
Haydon, 2010),we decided to investigate the effect of HupA and tacrine
on S100B secretion astrocyte cultures using HupA at concentrations
currently described in the literature (from 0.1 to 100 μM), as well
as cholinergic agonists. Our results suggest, for the ﬁrst time to our
knowledge, a cholinergic modulation of S100B secretion.
Material and methods
Animals
Twenty newborn Wistar rats (1 or 2-days old) (used for astrocyte
cultures) and twelve male 30-day old rats (used for hippocampal slice
preparations) were obtained from our breeding colony (at the
Department of Biochemistry, Universidade Federal do Rio Grande do
Sul, Brazil). Rats were maintained under controlled light and environ-
mental conditions (12 h light/12 h dark cycle at a constant temperature
of 22±1 °C) with free access to food and water. All animal experiments
were carried out in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH Publications
No. 80–23), revised 1996, and following the regulations of the local
animal house authorities (Approval 20375).
Drugs and reagents
(−)Huperzine A, tacrine, acetylthiocholine, nicotine, mecamylamine,
carbachol, scopolamine, poly-L-lysine, monoclonal anti-S100B antibody
(SHB1), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
o-phenylenediamine (OPD) andmethylthiazolyldiphenyltetrazolium
bromide (MTT) were purchased from Sigma (St. Louis, USA).
Fetal calf serum (FCS), Dulbecco's modiﬁed Eagle's medium (DMEM)
and other materials for cell culture were purchased from Gibco
(Carlsbad, USA). Polyclonal anti-S100B and anti-rabbit linked peroxi-
dase were purchased from DAKO (São Paulo, Brazil) and GE (Little
Chalfont, United Kingdom), respectively.
Astrocyte cultures
Primary astrocyte cultures from Wistar rats were prepared as
previously described (Gottfried et al., 1999). Brieﬂy, cerebral cortices
of newborn Wistar rats were removed and mechanically dissociated
in Ca2+- and Mg2+-free balanced salt solution, pH 7.4, containing
(in mM): 137 NaCl; 5.36 KCl; 0.27 Na2HPO4; 1.1 KH2PO4 and 6.1
glucose. The cortices were cleaned of meninges and mechanically
dissociated by sequential passages through a Pasteur pipette. After
centrifugation at 1400 RPM for 5 min, the pellet was resuspended
in DMEM (pH 7.6) supplemented with 8.39 mM HEPES, 23.8 mM
NaHCO3, 0.1% amphotericin, 0.032% gentamicin and 10% fetal calf
serum. The cells were plated at a density of 1.5×105 cells/cm2 in 24
well plates pre-coated with poly-L-lysine. Cultures were maintained
in DMEM containing 10% FCS in 5% CO2/95% air at 37 °C, allowed to
grow to conﬂuence, and used in vitro at 15 days. Immunocytochemistry
for glial ﬁbrillary acidic protein (GFAP), a speciﬁc protein for astrocytes,
indicated a cell purity of higher than 95% (data not shown). Treatments
consisted of HupA (0.1, 1, 10 and 100 μM), tacrine (10 and 100 μM),
acetylthiocholine (10 and 100 μM), nicotine, mecamylamine, carbachol
and scopolamine, all these last four drugswere used at 1–1000 μM, for 1
and 24 h at 37 °C. Drug concentrations were chosen based on pilot
experiments. All experiments were performed in triplicate. Afterwards,the collected culturemediumand the cell lysateswere stored at−20 °C
until used in assays for S100B.
Hippocampal slices
Hippocampal slices were prepared as previously described (Nardin
et al., 2009). Thirty-day old Wistar rats were killed by decapitation
and the brains were removed and placed in cold saline medium
with the following composition (in mM): 120 NaCl; 2 KCl; 1 CaCl2; 1
MgSO4; 25 HEPES; 1 KH2PO4, and 10 glucose, adjusted to pH 7.4
and previously aerated with O2. The hippocampi were dissected and
transverse slices of 0.3 mm were obtained using a McIlwain Tissue
Chopper. Slices were then transferred immediately to 24-well culture
plates, each well containing 0.3 ml of physiological medium and only
one slice. The medium was changed every 15 min for 2 h at room
temperature. After this stabilization period, the drugs were added
and the slices incubated for 1 h at 30 °C. Treatments were the same as
those used in astrocyte cultures.
Fig. 2. Effect of tacrine on S100B secretion and content. Astrocyte cultures were incubated with tacrine (10 and 100 μM). S100B levels in the medium were measured for 1 h (A) and
24 h (B), as well as the S100B content (C) by ELISA. Each value is the mean (± standard error) of ﬁve independent experiments performed in triplicate, expressed as a percentage of
the control (indicated by line). *pb0.05 and **pb0.01 compared to control (one-way ANOVA followed by Dunnet's post-hoc assay).
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S100B levels were measured by enzyme-linked immunosorbent
assay (ELISA), as previously described (Leite et al., 2008). Brieﬂy, 50 μl
of sample plus 50 μl of Tris buffer were incubated for 2 h in amicrotiter
plate previously coated with monoclonal anti-S100B. Polyclonal
anti-S100 was incubated for 30 min and then peroxidase-conjugated
anti-rabbit antibody was added for a further 30 min. The color reaction
with o-phenylenediamine was measured at 492 nm. The standard
S100B curve ranged from 0.002 to 1 ng/ml.
Cell viability and integrity
Cell viabilitywas assayed by the colorimetricMTT reductionmethod
(Hansen et al., 1989) and by neutral red incorporation (Leite et al.,
2009). For the MTT reduction, cells were incubated with 0.5 mg/ml of
MTT at 37 °C for 30 min. The formazan product generated during the
incubation was solubilized in dimethyl sulfoxide (DMSO). Absorbance
values were measured at 560 and 630 nm. The neutral red assay was
carried out by treating cells with 50 μg/ml neutral red (NR) at 37 °C
for 30 min. Afterwards, the cells were rinsed twice with PBS for 5 min
each and NR dye taken up by viable cells was extracted with acetic
acid/ethanol/water (1/50/49). Absorbance values were measured at
560 nm. Cell integrity was indicated by lactate dehydrogenase (LDH)
activity in the incubation medium. Determination was carried out by a
colorimetric commercial kit (Doles Reagentes e Equipamentos para
Laboratórios Ltda., Brazil), according to themanufacturer's instructions.
Results were expressed as percentages of the control.
Statistical analysis
Data were analyzed by one-way ANOVA followed by Dunnet's
post hoc test. Results represent mean±S.E.M. GraphPad Prism 5 for
Windows was used for statistical analysis; pb0.05 was set as statisti-
cally signiﬁcant, and values of signiﬁcance were indicated by differentTable 1
Viability and integrity of astrocyte cultures and hippocampal slices treated with HupA,
at 10 or 100 μM, for 24 h and 1 h, respectively.
Astrocyte cultures Hippocampal slices
NR LDH NR LDH
HupA (10 μM) 100.0±7.7 114.2±9.3 119.2±1.3 99.0±7.3
HupA (100 μM) 110.3±9.5 105.8±7.0 123.1±4.8 94.1±1.4
NR, neutral red uptake; LDH, lactate dehydrogenase activity. Data are expressed as
percentage of control and represent mean±S.E.M.symbols: one asterisk (*) for pb0.05; two asterisks (**) for pb0.01;
and three asterisks (***) for pb0.001.
Results
Huperzine A, but not tacrine, stimulates S100B secretion in astrocyte cultures
We investigated S100B secretion in astrocyte cultures by adding
concentrations of HupA from 0.1 to 100 μM (Fig. 1A). HupA at
100 μM induced an increase in S100B secretion at 1 h (F4, 25=
6.608, p=0.0009). However, no changes were observed in secretion
(Fig. 1B) or in the intracellular S100B content (Fig. 1C) at 24 h after-
wards. In contrast, tacrine at 10 or 100 μM was not able to alter S100B
secretion at 1 h (Fig. 2A) and at 24 h (Fig. 2B). Nevertheless, tacrine
at both concentrations was able to reduce the intracellular content of
S100B at 24 h (Fig. 2C) (F2, 14=7.058, p=0.0076).
Huperzine A exposure did not affect cell integrity or viability
In order to evaluate cell integrity and viability of astrocytes
exposed to HupA for 24 h, at two higher concentrations (10 and
100 μM), we carried out 3 assays: LDH activity, neutral red assay
and MTT reduction assay. No signiﬁcant differences were observed
in extracellular LDH activity, suggesting that cell integrity was pre-
served duringHupA exposure (Table 1). Two other assays for cell viabil-
ity, neutral red assay (Table 1) and MTT reduction assay (data not
shown), were not modiﬁed by HupA.
Acetylthiocholine, like Huperzine A, stimulated S100B secretion in
astrocyte cultures
Acetylthiocholine is the substrate used for measurement of AChE
activity and also works as a cholinergic agonist. This compound,
at 100 μM, increased S100B secretion in astrocyte cultures at 1 h
(Fig. 3A) (F2, 13=21.04, p=0.0001). No changes in S100B secretion
(Fig. 3B) or S100B content (Fig. 3C) were observed at 24 h.
Cholinergic modulation of S100B secretion in astrocyte cultures
Results for tacrine and acetylthiocholine suggest that the effect
of HupA on S100B secretion was independent of AChE inhibition and
possibly involves cholinergic regulation. Therefore, we investigated
the involvement of cholinergic modulation in basal S100B secretion in
astrocyte cultures. Four compoundswere used: nicotine,mecamylamine
(a nicotinic antagonist), carbachol (a muscarinic agonist) and scopol-
amine (a muscarinic antagonist), at concentrations from 1 to 1000 μM.
Fig. 3. Effect of acetylthiocholine on S100B secretion and content. Astrocyte cultures were incubated with acetylthiocholine (10 and 100 μM). S100B levels in the medium were
measured for 1 h (A) and 24 h (B), as well as the S100B content (C) by ELISA. Each value is the mean (± standard error) of ﬁve independent experiments performed in triplicate,
expressed as a percentage of the control (indicated by line). ***pb0.001 compared to control (one-way ANOVA followed by Dunnet's post-hoc assay).
Fig. 4. Effect of nicotine-induced S100B secretion and content. Astrocyte cultures were
incubated with nicotine (1, 10, 100 and 1000 μM) and the S100B levels in the medium
were measured for 1 h (A) and 24 h (B), as well as the S100B content (C) by ELISA.
Each value is the mean (± standard error) of ﬁve independent experiments performed
in triplicate and expressed as a percentage of the control (indicated by dashed line).
**pb0.01 compared to control (one-way ANOVA followed by Dunnet's post-hoc assay).
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(Fig. 4A), we observed an increase in S100B secretion at 1 h (F4, 46=
5.134, p=0.0017). No changes were observed in S100B secretion
(Fig. 4B) or S100B intracellular content (Fig. 4C) at 24 h. Expectedly,
mecamylamine was not able to change S100B secretion at 1 h
(Fig. 5A), but increased S100B secretion at 24 h (Fig. 5B) (F4, 22=
12.30, p=0.0001). No changes, induced by mecamylamine, were
observed in the S100B intracellular content (data not shown). Mecamyl-
amine (at 1 mM) blocked the increase in S100B secretion induced by
HupA, and also blocked the effect of nicotine (Fig. 5C) (F3, 33=9.519,
p=0.0001). No changes in S100B secretion or content were observed
when carbachol or scopolamine was added to astrocyte cultures (data
not shown).
S100B secretion was reduced by Huperzine A and acetylthiocholine in
fresh hippocampal slices
Finally we evaluated the effect of HupA on basal S100B secretion
in acute hippocampal slices. Surprisingly, HupA at 100 μM decreased
S100B secretion in this preparation (Fig. 6A) (F4, 53=5.165, p=
0.0014). This effect also occurred with acetylthiocholine at 100 μM
(Fig. 6B, F2, 22=12.51, p=0.0002), but not with tacrine at 100 μM
(data not shown). Nicotine at 100 and 1000 μM (Fig. 6C) did not
signiﬁcantly change S100B secretion, but at lower concentrations (1 and
10 μM) we observed an increase in S100B secretion (F4, 37=3.628, p=
0.0136).
Discussion
HupA has been used in schizophrenia and AD in China and has
been proposed as a selective, reversible, and well-tolerated inhibitor
of AChE, and an even more potent inhibitor of AChE than tacrine,
donepezil, rivastigmine or galanthamine in vivo (Ma et al., 2007;
Wang et al., 2009). However, most of the clinical trials that have
employed this compound have been performed in China and this sub-
stance has not been approved by the Food and Drug Administration
(FDA) in the USA or by the National Agency of Sanitary Vigilance
(ANVISA) in Brazil yet. As such, the characterization of some putative
effects of this compound on some neurochemical targets is necessary.
We herein analyzed the effect of HupA on S100B secretion,
assumed to be a marker of activation of astrocytes (Donato et al.,
2009; Goncalves et al., 2008), which play an important role in both
physiological and pathological brain processes (Halassa and Haydon,
2010; Rodriguez et al., 2009; Verkhratsky, 2006). Recent studies
have emphasized the role of astrocytes (via nicotinic and muscarinic
receptors) in cholinergic neurotransmission and long-term potentia-
tion (LTP) (Navarrete et al., 2012; Shen and Yakel, 2012). Moreover,a role of extracellular S100B in LTP has been previously reported
(Nishiyama et al., 2002).
Our results indicate that HupA is able to induce an increase in
S100B secretion in cortical astrocytes in culture, but a decrease in
S100B secretion in acute hippocampal slices. These opposing effects
Fig. 5. Effect of mecamylamine-induced S100B secretion and content. Astrocyte cultures
were incubated with mecamylamine (1, 10, 100 and 1000 μM) and the S100B levels
in the medium were measured for 1 h (A) and 24 h (B). In C, astrocyte cultures were
incubated with mecamylamine (MECA, at 1 mM) and nicotine (NIC, at 1 mM) or
Huperzine A (HupA, at 100 μM) for 1 h. S100B levels in the medium were measured
by ELISA. Each value is the mean (± standard error) of ﬁve independent experiments
performed in triplicate and expressed as a percentage of the control (indicated by
dashed line). *pb0.05 and ***pb0.001 compared to control (one-way ANOVA followed
by Dunnet's post-hoc assay).
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induces S100B secretion in astrocyte cultures, but a decrease in
hippocampal slices (Leite et al., 2009). Such discrepancies can be
attributed to differences in cell signaling between isolated cells and the
complex cell environment of slice preparation and/or the heterogeneity
of astrocyte populations from different brain regions. Moreover, under
our conditions, no differences were found in relation to cell integrity
or viability in either preparation.
Our results regarding the increase in S100B secretion in cortical
astrocytes suggest a trophic role of HupA, based on the in vitro
neurotrophic activity of S100B (Donato et al., 2009; Serbinek et al.,
2010) and based on the acute administration of this protein in vivo
after brain injury (Kleindienst and Ross Bullock, 2006). In contrast,
tacrine was not able to induce S100B secretion in astrocyte cultures
(or a decrease in hippocampal slices). This result suggests that themodulation of S100B secretion by HupA is independent of AChE
inhibition, but does not rule out a possible effect of HupA on cholinergic
neurotransmission.
Conﬁrming this possibility, a similar effect to that of HupA on S100B
secretion was also obtained with acetylthiocholine, a cholinergic
agonist, in both cortical astrocytes and hippocampal slices. Nicotine
was also able to induce S100B secretion in astrocyte cultures (at con-
centrations of 100 and 1000 μM) and in hippocampal slices (at con-
centrations of 1 and 10 μM). The Huperzine A or nicotine-induced
S100B secretion in astrocyte cultures was blocked by mecamylamine,
a non-selective nicotinic antagonist. Moreover, in astrocyte cultures
mecamylamine did not affect basal S100B secretion at 1 h, but
was able to increase S100B secretion 24 h later. No effect on acute
basal S100B secretion was observed with the addition of carbachol, a
muscarinic agonist, or scopolamine, a muscarinic antagonist. Therefore,
these data suggest a speciﬁc involvement of nicotinic receptors in the
modulation of S100B secretion in astrocyte cultures.
The mechanism by which HupA affects S100B secretion remains
unclear, butwemaymake some speculations regarding the involvement
of cholinergic and/or NMDA receptors. Studies on the displacement
of [H3]QNB- and [H3](−)nicotine-speciﬁc binding showed that
HupA has a direct effect on cholinergic receptors (Tang et al., 1989).
However, there are no data about binding or the direct action of HupA
on cholinergic presynaptic receptors and the control of acetylcholine
release (Wang et al., 2006). On the other hand, HupA was able to block
the release of TNF-alpha, an inﬂammatory cytokine, in cultures of
microglial cells submitted to hypoxia, and this effect was antagonized
by mecamylamine (Wang et al., 2012). In agreement with this, our
data reinforce the involvement of nicotinic receptors in HupA activity.
Moreover, it has been proposed that HupA acts as an NMDA antagonist
(Gordon et al., 2001). This possibly should be investigated, however
NMDA was unable to induce S100B secretion in astrocyte cultures
(Goncalves et al., 2002).
As mentioned before HupA has also been used in the treatment
of schizophrenia in China (Ma et al., 2007). Antipsychotic drugs
(putatively acting on dopamine receptors) are reported to modulate
S100B secretion (Nardin et al., 2011; Steiner et al., 2009). Therefore,
it would be interesting to evaluate whether the modulation of
S100B secretion by HupA also involves dopamine receptors.Conclusions
Our data reinforce the idea that AChE inhibitors, particularly
HupA, do not act exclusively on the acetylcholine balance. HupA,
per se, could be acting via nicotinic receptors, at least with regards
to astroglial S100B secretion. This action could contribute to improve
the cognitive deﬁcit observed in AD patients, which is attributed to
cholinergic dysfunction. This reinforces the importance of astrocytes
as targets of neuroactive compounds in brain diseases. In addition,
for the ﬁrst time, to our knowledge, these data indicate that S100B
secretion can be modulated by nicotinic receptors, in addition to
glutamate, dopamine and serotonin receptors.Conﬂict of interest statement
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